Breakthroughs in Cancer Gene Therapy: Researchers Seek to Harness p53 Gene's Power

Recent research by Binzhou Medical University has highlighted the significance of the p53 gene in cancer treatment, despite challenges in developing effective therapies. The p53 gene, a nuclear transcription factor, has been labeled "undruggable" due to its characteristics, but promising strategies have emerged to target proteins considered previously inaccessible. These advancements include novel techniques, small molecules, and genetic therapy approaches. While obstacles persist in clinical development, researchers remain optimistic about the potential of p53-based therapies.

Key Takeaways:

• The p53 gene is frequently mutated in various cancers, prompting efforts to restore its function as a therapeutic approach.
• Despite its potential, only a limited number of drug development initiatives have progressed to late-stage clinical trials, and no p53-targeted therapies have received approval in the USA or Europe.
• Recent strategies have emerged to target proteins traditionally considered "undruggable," including small molecules, genetic therapy, and nanotechnology-based approaches.
• Advancements in mutant p53 biology, compound mechanisms, and treatment modalities have opened up new avenues for p53-based therapies.
• A review reassesses the progress in targeting p53-mutant cancers, discusses obstacles in translating these approaches into effective therapies, and highlights p53-based therapies via nanotechnology.
• Researchers are working on small molecules that can restore the tumor-suppressive functions of mutant p53 proteins and are developing drugs specifically designed for particular p53 mutation types.
• Genetic therapy strategy and approaches have rekindled interest in p53-based therapies, with a growing focus on treating specific p53 mutations.

Statistics:

• 15% of cancers have mutations in the p53 gene (Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers).
• 763 (Biomolecules, 2025 edition) articles published on Biomolecules in 2025, including the free version of the journal article.
• 6 (Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers) authors are associated with the research, including Na Zhang, Zhiyuan Jing, Jie Song, Qiyue Liang, Yuxue Xu, Zhaowei Xu, Longping Wen, Pengfei Wei.
• 264003, Yantai, People's Republic of China, is the location of the School of Pharmacy, Binzhou Medical University (Na Zhang).

Sources:

• (Biomolecules - http://www.mdpi.com/journal/biomolecules).
• Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers. Biomolecules, 2025,15(6):763.
• MDPI AG is the publisher for Biomolecules.
• https://doi-org.sdpl.idm.oclc.org/10.3390/biom15060763.